Turalio (Pexidartinib Capsules)
Turalio (Pexidartinib) is used for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.
Dosage: The recommended turalio dose is 400 mg, administered twice daily on an empty stomach until the disease is progressive or unacceptable toxicity established. Swallow the capsules of turalio whole. Do not open, break, or chew the capsules. If a patient vomits or misses a dose, instruct the patient to take the next dose at its scheduled time.
Side Effects: The most commonly reported pexidartinib side effects include:
- Increased lactate dehydrogenase
- Increased aspartate aminotransferase
- Hair color changes
- Decreased neutrophils
- Increased cholesterol
- Increased alkaline phosphatase
- Decreased lymphocytes
- Eye edema
- Decreased hemoglobin
- Decreased phosphate
- Increased alanine aminotransferase
Warnings and Precautions:
- Permanently discontinue turalio uses in such patients who are unable to tolerate 200 mg orally twice in a day.
- Do not breastfeed during treatment with pexidartinib and for at least seven days following your final dose of pexidartinib.
- The pexidartinib 200 mg may affect fertility in females and males, which may affect your ability to have children. Talk to your health specialist if you have concerns about fertility.
- Avoid taking proton pump inhibitor medicines (PPIs) & St. John’s wort during therapy with turalio capsules because they can affect how this drug works.
- Females of reproductive potential are advised to use effective contraception during therapy with pexidartinib and for 30 days following the final dose.